

ELECTROPHYSIOLOGIC TESTING TO IDENTIFY PATIENTS WITH CORONARY ARTERY DISEASE WHO ARE AT RISK FOR SUDDEN DEATH

ALFRED E. BUXTON, M.D., KERRY L. LEE, PH.D., LORENZO DICARLO, M.D., MICHAEL R. GOLD, M.D.,
G. STEPHEN GREER, M.D., ERIC N. PRYSTOWSKY, M.D., MICHAEL F. O'TOOLE, M.D., ANTHONY TANG, M.D.,
JOHN D. FISHER, M.D., JAMES COROMILAS, M.D., MARIO TALAJIC, M.D., AND GAIL HAFLEY, M.S.,
FOR THE MULTICENTER UNSUSTAINED TACHYCARDIA TRIAL INVESTIGATORS*

ABSTRACT

Background The mortality rate among patients with coronary artery disease, abnormal ventricular function, and unsustained ventricular tachycardia is high. The usefulness of electrophysiologic testing for risk stratification in these patients is unclear.

Methods We performed electrophysiologic testing in patients who had coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and asymptomatic, unsustained ventricular tachycardia. Patients in whom sustained ventricular tachyarrhythmias could be induced were randomly assigned to receive either antiarrhythmic therapy guided by electrophysiologic testing or no antiarrhythmic therapy. The primary end point was cardiac arrest or death from arrhythmia. Patients without inducible tachyarrhythmias were followed in a registry. We compared the outcomes of 1397 patients in the registry with those of 353 patients with inducible tachyarrhythmias who were randomly assigned to receive no antiarrhythmic therapy in order to assess the prognostic value of electrophysiologic testing.

Results Patients were followed for a median of 39 months. In a Kaplan–Meier analysis, two-year and five-year rates of cardiac arrest or death due to arrhythmia were 12 and 24 percent, respectively, among the patients in the registry, as compared with 18 and 32 percent among the patients with inducible tachyarrhythmias who were assigned to no antiarrhythmic therapy (adjusted $P < 0.001$). Overall mortality after five years was 48 percent among the patients with inducible tachyarrhythmias, as compared with 44 percent among the patients in the registry (adjusted $P = 0.005$). Deaths among patients without inducible tachyarrhythmias were less likely to be classified as due to arrhythmia than those among patients with inducible tachyarrhythmias (45 and 54 percent, respectively; $P = 0.06$).

Conclusions Patients with coronary artery disease, left ventricular dysfunction, and asymptomatic, unsustained ventricular tachycardia in whom sustained ventricular tachyarrhythmias cannot be induced have a significantly lower risk of sudden death or cardiac arrest and lower overall mortality than similar patients with inducible sustained tachyarrhythmias. (N Engl J Med 2000;342:1937-45.)

©2000, Massachusetts Medical Society.

MORTALITY from cardiovascular disease continues to decline, but patients with coronary artery disease, left ventricular dysfunction, and asymptomatic ventricular arrhythmias remain at high risk for sudden or nonsudden death.¹⁻⁵ Although myocardial ischemia is responsible for many events, most sudden deaths and cardiac arrests among patients who have had a myocardial infarction result from reentrant ventricular tachycardia or fibrillation.⁶ Electrophysiologic testing has been used to stratify patients according to the risk of sudden death, but previous analyses of this approach have involved relatively small numbers of patients and relatively short follow-up periods (≤ 2 years).⁷⁻¹⁶

The primary objective of the Multicenter Unsustained Tachycardia Trial was to evaluate the efficacy of antiarrhythmic therapy guided by electrophysiologic testing in reducing the risk of sudden death and cardiac arrest among patients with coronary artery disease, left ventricular dysfunction, and asymptomatic, unsustained ventricular tachycardia.¹⁷ A secondary goal was to evaluate the usefulness of electrophysiologic testing for risk stratification in this group of patients. In this report, we describe the outcomes of patients in whom sustained ventricular tachyarrhythmias were not induced on electrophysiologic testing, and we compare the rates of death due to arrhythmia and of death from any cause among these patients with the rates among patients with inducible ventricular tachyarrhythmias who were randomly assigned to receive no antiarrhythmic therapy.

METHODS

Patients

The complete study protocol has been described previously.^{17,18} Patients at 85 study sites in the United States and Canada were

From Brown University School of Medicine and Rhode Island Hospital, Providence (A.E.B.); Duke University Clinical Research Institute, Durham, N.C. (K.L.L., G.H.); Michigan Heart, Ann Arbor (L.D.); the University of Maryland School of Medicine, Baltimore (M.R.G.); Arkansas Cardiology Clinic, Little Rock (G.S.G.); Northside Cardiology, Indianapolis (E.N.P.); Midwest Heart Research Foundation, Lombard, Ill. (M.E.O.); the University of Ottawa Heart Institute, Ottawa, Ont., Canada (A.T.); Montefiore Medical Center and Albert Einstein School of Medicine, Bronx, N.Y. (J.D.F.); Columbia University School of Medicine, New York (J.C.); and the Montreal Heart Institute, Montreal (M.T.). Address reprint requests to Dr. Buxton at the Division of Cardiology, Rhode Island Hospital, 2 Dudley St., Suite 360, Providence, RI 02905.

*The participants in the Multicenter Unsustained Tachycardia Trial are listed in the Appendix.

identified as having coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and asymptomatic, unsustained ventricular tachycardia (lasting for three or more beats or a maximum of 30 seconds). Patients who met these criteria were enrolled four or more days after the most recent myocardial infarction or revascularization procedure and at least 72 hours after the most recent documented instance of hemodynamic instability or myocardial ischemia. Written informed consent was obtained from all the patients before enrollment. The institutional review board at each study site approved the protocol.

Patients were excluded if they had a history of syncope or had sustained ventricular tachycardia or ventricular fibrillation more than 48 hours after the onset of acute myocardial infarction. Patients were also excluded if they had unsustained ventricular tachycardia that occurred only in the setting of drug-induced long-QT syndrome or acute myocardial ischemia or that was attributable to acute metabolic disorders or drug toxicity, or if they had symptomatic, unsustained ventricular tachycardia.

Protocol

An electrophysiologic study was performed without the use of antiarrhythmic drugs.¹⁸ The study included one to three extrastimuli at two right ventricular sites during two drive-cycle lengths. Stimulation was stopped if uniform, sustained ventricular tachycardia was reproducibly induced or if more than 15 complexes of polymorphic ventricular tachycardia or flutter with three extrastimuli were reproducibly induced. If cardioversion was required to terminate an induced arrhythmia, reproducibility was not required before the stimulation was stopped. Patients with sustained monomorphic ventricular tachycardia induced by any method of stimulation and those with sustained polymorphic ventricular tachycardia (including ventricular flutter and fibrillation) induced by one or two extrastimuli were randomly assigned in equal proportions to receive either antiarrhythmic therapy guided by the results of electrophysiologic testing or no antiarrhythmic therapy. Ventricular flutter (tachycardias with a cycle length of <220 msec and no isoelectric interval between consecutive QRS complexes) and fibrillation were considered to be polymorphic ventricular tachycardia.

Patients without inducible ventricular tachyarrhythmias were not treated with antiarrhythmic therapy and were followed in a registry. This registry also included patients in whom only unsustained ventricular tachycardia (lasting <30 seconds) was induced, patients with sustained polymorphic ventricular tachycardia that was induced only by three extrastimuli or burst pacing, and patients with sustained monomorphic ventricular tachycardia that could not be reproduced.

Treatment of all the patients with beta-adrenergic–blocking agents and angiotensin-converting–enzyme inhibitors was strongly recommended. Patients were examined at the outpatient facility of one of the participating centers one month after discharge and every three months thereafter. The follow-up regimen was the same for the patients who underwent randomization and the patients in the registry.

Study End Points

The primary end point was cardiac arrest from which the patient was resuscitated or death due to arrhythmia. Secondary end points included death from all causes, death from cardiac causes, and spontaneous, sustained ventricular tachycardia. Deaths were classified according to a modification of the Hinkle–Thaler system.¹⁹ Deaths classified as due to arrhythmia included unwitnessed deaths, witnessed deaths that were instantaneous, nonsudden deaths due to incessant ventricular tachycardia, deaths considered to be sequelae of cardiac arrest, deaths caused by toxic effects of antiarrhythmic drugs, and deaths caused by complications of implanted defibrillators. Deaths in patients with end-stage heart failure or cardiogenic shock were not classified as sudden. Cardiac arrest was defined as a sudden loss of consciousness requiring direct-current countershock to restore consciousness or a stable blood pressure and rhythm.

Analysis of Events

Investigators at each study site provided a narrative description of the clinical circumstances surrounding all deaths and cardiac arrests, with accompanying electrocardiographic recordings, relevant hospital records, and laboratory data (when available). The data-coordinating center then edited the descriptions and documents to ensure that members of the events committee would be able to classify outcomes without knowing the results of the baseline electrophysiologic studies, the patients' randomization status, or whether a defibrillator had been implanted. The edited description of each event, including the supporting source documents and case-report forms, was then reviewed independently by two members of the events committee, each of whom classified the event according to the definitions of the study end points. If these two members disagreed on the classification, the event was reviewed by the entire events committee, which arrived at a classification by consensus.

Statistical Analysis

Values for continuous variables are presented as medians with 25th and 75th percentiles, and values for categorical variables are presented as percentages. Differences in clinical characteristics and medication use at base line between the patients in the registry and the patients with inducible ventricular tachyarrhythmias who were randomly assigned to no antiarrhythmic therapy were assessed with use of the Wilcoxon rank-sum test (for continuous variables) or the chi-square test or Fisher's exact test (for categorical variables). All tests of significance were two-tailed. Cumulative event rates were calculated by the Kaplan–Meier method, with the time to a first event as the outcome variable.²⁰ The statistical significance of differences in outcome between the two groups was assessed with the log-rank test.²¹

In addition, covariate-adjusted analyses of outcomes among the registry patients and the patients with inducible ventricular tachyarrhythmias who were assigned to no antiarrhythmic therapy were performed with the Cox proportional-hazards model.²² Covariates included in these analyses were age; sex; race; the time of enrollment relative to the start of the trial; the ejection fraction; whether the patient had had a previous myocardial infarction, had undergone bypass surgery, had undergone angioplasty, or had a history of angina; and whether the patient used beta-blockers. Covariate-adjusted comparisons were also performed of the outcomes among three subgroups of the patients in the registry (patients without inducible tachyarrhythmias, patients in whom only unsustained ventricular tachycardia was induced, and patients in whom sustained polymorphic ventricular tachycardia was induced only by three extrastimuli). Relative risks, expressed as hazard ratios (with 95 percent confidence intervals), were calculated with use of the Cox proportional-hazards model.

To compare the patients randomly assigned to no therapy and the patients in the registry with respect to types of events, the proportions of total events in each group that were classified as arrhythmia were compared with use of a conventional chi-square test.

RESULTS

We enrolled 2202 patients in the study, including 767 patients with inducible sustained ventricular tachyarrhythmias. Of these 767 patients, 704 agreed to undergo random group assignment, and 353 were subsequently assigned to receive no antiarrhythmic therapy. There were 1435 patients in the registry: 661 in whom no ventricular tachyarrhythmia was induced, 531 in whom only unsustained ventricular tachycardia was induced, and 205 with sustained polymorphic ventricular tachycardia induced only by three extrastimuli or burst pacing, as well as 38 additional patients whom we excluded from the present analy-

TABLE 1. CLINICAL CHARACTERISTICS OF THE PATIENTS AT BASE LINE.*

VARIABLE	PATIENTS IN THE REGISTRY (N=1397)	PATIENTS WITH INDUCIBLE VENTRICULAR TACHYARRHYTHMIAS AND NO ANTIARRHYTHMIC THERAPY (N=353)	P VALUE
Age (yr)	67 (59–72)	66 (58–72)	0.66
Male sex (%)	84	90	0.003
White race (%)	84	86	0.53
Spontaneous unsustained ventricular tachyarrhythmia			
No. of episodes/day	2 (1–8)	2 (1–5)	0.09
Mean duration of unsustained ventric- ular tachyarrhythmia (no. of complexes)	5 (4–8)	5 (4–8)	0.64
Ejection fraction (%)	29 (21–35)	29 (22–35)	0.54
History of myocardial infarction (%)	87	94	0.002
Previous thrombolytic therapy	18	21	0.15
Time between most recent myocardial in- farction and enrollment (%)			0.10
≤1 mo	16	18	
≤1 yr	43	38	
>3 yr	45	52	
Previous coronary bypass grafting (%)	63	56	0.02
Previous angioplasty (including stents) (%)	23	23	0.99
Uniform, sustained ventricular tachyar- rhythmia induced at base line (%)	0	92	
Cycle length of uniform ventricular tachyarrhythmia induced at base line (msec)	—	250 (230–272)	
NYHA class (%)†			0.84
I	37	36	
II	39	38	
III	24	25	
IV	0	0	

*Continuous variables are presented as medians, with 25th and 75th percentiles in parentheses; categorical variables are presented as percentages.

†Data were available for 666 patients in the registry and for 196 patients with ventricular tachyarrhythmias who were randomly assigned to no antiarrhythmic therapy. Because of rounding, not all percentages total 100. NYHA denotes New York Heart Association.

sis. Of the 38 excluded patients, 24 had inducible sustained monomorphic ventricular tachycardia that was not reproducible; 10 had inducible sustained monomorphic ventricular tachycardia, but no attempt was made to reproduce the findings; and 4 had sustained polymorphic ventricular tachycardia that was induced with two extrastimuli but that was not reproducible. Complications of the base-line electrophysiologic study occurred in 7 of the 2202 enrolled patients (0.3 percent). Thus, in this analysis we compared the outcomes of the 353 patients with inducible sustained tachyarrhythmias who were randomly assigned to no antiarrhythmic therapy with the outcomes of the 1397 patients in the registry.

Characteristics of the Patients

The clinical characteristics of the patients in the registry were similar in most respects to those of the patients with inducible ventricular tachyarrhythmias who were assigned to no antiarrhythmic therapy (Ta-

ble 1). However, the registry included greater proportions of women and of patients who had previously undergone bypass surgery. The group assigned to no antiarrhythmic therapy included significantly more patients who had a history of myocardial infarction.

Medical Therapy

At the time of discharge from the hospital, 35 percent of the registry patients were taking beta-blockers, as compared with 51 percent of the patients assigned to no antiarrhythmic therapy (P=0.001) (Table 2). At the last follow-up, use of beta-blockers had increased to 45 percent and 53 percent, respectively, among the surviving patients. Most patients in both groups were taking angiotensin-converting-enzyme inhibitors and aspirin at the time of discharge (Table 2).

Antiarrhythmic Therapy

At the time of discharge from the hospital, 97 percent of the registry patients were not receiving anti-

TABLE 2. MEDICATIONS AT DISCHARGE FROM THE HOSPITAL.*

MEDICATION	PATIENTS IN THE REGISTRY (N=1397)	PATIENTS WITH INDUCIBLE VENTRICULAR TACHYARRHYTHMIAS AND NO ANTIARRHYTHMIC THERAPY (N=353)	P VALUE
		percent	
Beta-blocker	35	51	0.001
Angiotensin-converting-enzyme inhibitor	72	77	0.06
Aspirin	60	63	0.29
Digitalis	57	53	0.21
Diuretic agent	59	58	0.75
Calcium-channel-blocking agent	20	25	0.05
Nitrate	42	44	0.44

*There were no substantial changes in the percentages of patients receiving these medications at the time of their last follow-up, with the exception of beta-blockers.


arrhythmic therapy, 2 percent (33 patients) were taking an antiarrhythmic drug, and less than 1 percent (3 patients) had received an implantable defibrillator. At the last follow-up, 84 percent of the registry patients were receiving no antiarrhythmic therapy, 12 percent (163 patients) were receiving an antiarrhythmic drug, and 4 percent (61 patients) had received a defibrillator. Of the patients with a defibrillator, 75 percent (46 patients) had received the device after a cardiac arrest, an episode of sustained ventricular tachycardia, or an episode of syncope.

At the time of discharge from the hospital, 96 percent of the patients with inducible ventricular tachyarrhythmias who were randomly assigned to no therapy were receiving no antiarrhythmic therapy, 2 percent (6 patients) had been given a defibrillator, and 2 percent (8 patients) were receiving antiarrhythmic drugs. At the last follow-up, 72 percent of these patients were not receiving antiarrhythmic therapy, 11 percent (38 patients) were receiving an antiarrhythmic drug, and 18 percent (62 patients) had received a defibrillator. Of the patients with a defibrillator, 79 percent (49 patients) had received the device after a cardiac arrest, spontaneous sustained ventricular tachycardia, or syncope.

Follow-up

The median duration of follow-up was 41 months for the patients in the registry and 37 months for the patients randomly assigned to no antiarrhythmic therapy. All but 16 of the registry patients and all but 5 of the randomly assigned patients (99 percent in each case) were followed for two or more years. Thirty-two percent of the patients in each of these groups were followed for five or more years. Information adequate to classify events was available for all but 19 (1 percent) of the registry patients and all but 1 (<1 percent) of the patients who underwent randomization.

Two-year and five-year rates for the primary end point of cardiac arrest or death due to arrhythmia, calculated by Kaplan–Meier methods, were 12 percent and 24 percent, respectively, among the registry patients. The corresponding rates for patients with in-



No. AT RISK						
Inducible tachyarrhythmias, no antiarrhythmic therapy	353	290	242	178	118	67
Registry	1397	1212	1074	787	530	308

Figure 1. Kaplan–Meier Estimates of the Rates of Cardiac Arrest or Death from Arrhythmia in the Registry Patients and the Patients with Inducible Ventricular Tachyarrhythmias Who Were Not Assigned to Antiarrhythmic Therapy.

ducible ventricular tachyarrhythmias who were assigned to no antiarrhythmic therapy were 18 percent and 32 percent (unadjusted $P=0.005$ by the log-rank test and covariate-adjusted $P<0.001$ for the five-year period) (Fig. 1 and Table 3). Overall mortality rates after two and five years were 21 percent and 44 percent, respectively, among the registry patients, as compared with 28 percent and 48 percent among the patients assigned to no antiarrhythmic therapy (unadjusted $P=0.09$ and covariate-adjusted $P=0.005$ for the five-year period) (Fig. 2 and Table 3). The increased significance of the difference in mortality between the randomly assigned patients and the patients in the registry after adjustment for covariates was largely due to the imbalance in the use of beta-blockers between these two groups.

The proportion of deaths classified as resulting from arrhythmia was higher among the patients randomly assigned to no antiarrhythmic therapy (54 percent) than among the registry patients (45 percent) ($P=0.06$). Spontaneous sustained ventricular tachycardia not associated with cardiac arrest also occurred more often among patients with inducible ventricular tachyarrhythmias (21 percent) than among the patients in the registry (6 percent) over the five-year follow-up.

The rates of cardiac arrest or death due to arrhythmia and of death from all causes were very similar among the three subgroups of patients in the registry (Table 4). The differences among these subgroups with respect to the rate of cardiac arrest or death due to arrhythmia and the rate of death from all causes were not statistically significant after adjustment for base-line imbalances among the groups in key prognostic factors such as the ejection fraction, age, and the use of beta-blockers (Table 4).

DISCUSSION

The results of this study indicate that among patients with coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and spontaneous, unsustained ventricular tachycardia, the induction of sustained ventricular tachyarrhythmias by programmed stimulation identifies patients who are at significantly greater risk for sudden death due to cardiac causes or death from any cause than patients without inducible tachyarrhythmias. However, even patients without inducible tachyarrhythmias have a relatively high risk of death. The presence of inducible sustained ventricular tachycardia proved to be a relatively specific predictor of death from arrhythmia in this group of patients. The proportion of deaths classified as due to arrhythmia was greater among the patients with inducible tachyarrhythmias who were randomly assigned to no antiarrhythmic therapy than among the patients in the registry, in whom sustained tachyarrhythmias could not be induced.


Subgroup analysis of event rates among the patients in the registry, according to the type of induced arrhythmia (no inducible ventricular tachyarrhythmia, only unsustained ventricular tachycardia induced, or sustained polymorphic tachyarrhythmias induced only by three extrastimuli), suggests that there is no significant difference in risk among these three subgroups.

Previous analyses of the prognostic usefulness of electrophysiologic testing in patients with coronary disease and unsustained ventricular tachyarrhythmias have suggested that the negative predictive value of these tests with respect to sudden death is approximately 90 percent over follow-up periods of one to two years.¹²⁻¹⁶ We found that electrophysiologic testing had a negative predictive value of 88 percent for

TABLE 3. RATES OF EVENTS AMONG THE PATIENTS IN THE REGISTRY AND THE PATIENTS WITH INDUCIBLE VENTRICULAR TACHYARRHYTHMIAS WHO WERE RANDOMLY ASSIGNED TO NO ANTIARRHYTHMIC THERAPY.

VARIABLE	RATE OF CARDIAC ARREST OR DEATH FROM ARRHYTHMIA		OVERALL MORTALITY RATE	
	REGISTRY (N=1397)	NO ANTIARRHYTHMIC THERAPY (N=353)	REGISTRY (N=1397)	NO ANTIARRHYTHMIC THERAPY (N=353)
No. of events	260	90	572	158
Two-year rate (%)	12	18	21	28
Five-year rate (%)	24	32	44	48
Hazard ratio*				
Unadjusted	0.71 (0.56–0.90)		0.86 (0.72–1.02)	
P value	0.005		0.09	
Adjusted	0.66 (0.51–0.84)		0.77 (0.64–0.92)	
P value	<0.001		0.005	

*Values in parentheses are 95 percent confidence intervals. Covariates included in the adjusted model were age, sex, race, time of enrollment, history of myocardial infarction, history of bypass surgery, history of angioplasty, history of angina, ejection fraction, and use or nonuse of beta-blockers at hospital discharge. Hazard ratios refer to the entire five-year follow-up period.



No. AT RISK						
Inducible tachyarrhythmias, no antiarrhythmic therapy	353	296	248	184	123	71
Registry	1397	1217	1086	797	539	314

Figure 2. Kaplan–Meier Estimates of the Overall Mortality Rates in the Registry Patients and the Patients with Inducible Ventricular Tachyarrhythmias Who Were Not Assigned to Antiarrhythmic Therapy.

TABLE 4. RATES OF EVENTS AMONG THE PATIENTS IN THE REGISTRY, ACCORDING TO SUBGROUP.*

VARIABLE	RATE OF CARDIAC ARREST OR DEATH FROM ARRHYTHMIA					OVERALL MORTALITY RATE					
	ONLY UNSUSTAINED		POLYMORPHIC SUSTAINED		UNADJUSTED P VALUE	ONLY UNSUSTAINED		POLYMORPHIC SUSTAINED		UNADJUSTED P VALUE	ADJUSTED P VALUE†
	NO VT INDUCED (N=661)	VT INDUCED (N=531)	VT INDUCED (N=205)	VT INDUCED (N=205)		NO VT INDUCED (N=661)	VT INDUCED (N=531)	VT INDUCED (N=205)			
No. of events	123	85	52	0.13	0.27	286	204	82	0.03	0.49	
Two-year rate (%)	13	10	14			24	19	17			
Five-year rate (%)	26	22	28			49	40	40			

*P values are for the comparison of the three groups, with two degrees of freedom, and refer to the rate of events over the entire five-year period. VT denotes ventricular tachyarrhythmia.

†Covariates included in the adjusted model were age, sex, race, time of enrollment, history of myocardial infarction, history of bypass surgery, history of angioplasty, history of angina, ejection fraction, and use or nonuse of beta-blockers at hospital discharge.

cardiac arrest or death due to arrhythmia within two years in the registry patients. The current results indicate that the risk of cardiac arrest or death due to arrhythmia in the study population persists over a median follow-up of nearly 3.5 years.

The prognostic usefulness of electrophysiologic testing has also been studied in a group of patients slightly different from ours — one made up of survivors of recent myocardial infarction (less than one month before enrollment), without regard to left ventricular function or the presence of spontaneous arrhythmias.⁷⁻¹¹ These studies reported rates of arrhythmic events ranging from less than 1 percent to 3 percent among patients without inducible ventric-

ular tachyarrhythmias over follow-up periods of one to two years. The higher rates of events in the present study are probably due to several characteristics of our patient population, including the reduced ejection fraction and the presence of unsustained ventricular tachycardia, which were criteria for enrollment.

A documented myocardial infarction was not required for entry into the trial, but we did require patients without infarction to have left ventricular dysfunction that was presumed to be due to coronary disease on the basis of coronary anatomy. Only 87 percent of the registry patients had a history of infarction, as opposed to 94 percent of the patients with inducible ventricular tachyarrhythmias who were

assigned to no therapy. Mechanisms of sudden death among patients with left ventricular dysfunction but no history of infarction probably differ from those among patients with a previous infarction, and programmed stimulation may not provoke tachycardia in the former patients.²³⁻²⁷

A previous analysis of data on our patients identified several factors in addition to myocardial infarction that differentiate patients in whom ventricular tachyarrhythmias can be induced from those without inducible ventricular tachyarrhythmias.²⁸ Sustained tachyarrhythmias were significantly more likely to be induced in patients who were male, patients who were white, and patients who had recent angina (within six weeks before enrollment), left ventricular dyskinesis, or greater numbers of fixed defects on thallium imaging. The rate of inducible ventricular tachyarrhythmias increased progressively with increasing numbers of diseased coronary arteries. In addition, inducibility of ventricular tachyarrhythmias was more likely in patients who had had an infarction complicated by congestive heart failure 48 hours or more after the onset of symptoms or complicated by ventricular tachycardia or fibrillation 48 hours or less after the onset of symptoms. Thus, several potentially important prognostic factors differentiated registry patients from those with inducible tachyarrhythmias. These factors could influence the efficacy of therapy; for instance, patients without inducible tachyarrhythmias might not respond as favorably to implantable defibrillators as patients with inducible tachyarrhythmias.¹⁷

The negative predictive value of electrophysiologic testing that we calculated may be viewed as lower than expected. However, the 12 percent rate of death due to arrhythmia among our registry patients at two years is similar to the rates of 8 to 13 percent reported previously.¹²⁻¹⁵ It is to be expected, in a population of patients with coronary disease as severe as that in our patients, that the risk of death from all causes and the risk of sudden death will persist over a five-year period. There are other possible explanations for arrhythmic events in patients without inducible sustained ventricular tachycardia. The results of electrophysiologic testing vary from day to day and over the long term by 10 to 50 percent.²⁹⁻³³ It is also likely that progression of coronary disease, resulting in the formation of new circuits that can cause reentrant tachycardia or sudden death due to recurrent ischemia, will occur. The former problem might be detected by periodic repetition of electrophysiologic testing in patients who are identified as potentially at risk. Finally, cardiac disease progressed in many of our patients during follow-up, causing the development of heart failure, with its attendant risk of sudden death.

In conclusion, the results of electrophysiologic testing can be used to assess the prognosis of patients with coronary disease, left ventricular dysfunction, and

unsustained ventricular tachycardia, but the value of this information may diminish with time.

Supported by grants from the National Heart, Lung, and Blood Institute (UO1 HL45700 and UO1 HL45726), C.R. Bard, Berlex Laboratories, Boehringer-Ingelheim Pharmaceuticals, Guidant, Knoll Pharmaceutical, Medtronic, Merck, Searle, Ventritex, and Wyeth-Ayerst Laboratories. Dr. DiCarlo is currently an employee of Guidant.

APPENDIX

The following persons and institutions participated in the Multicenter Unsustained Tachycardia Trial: **Executive Committee:** A.E. Buxton, K.L. Lee (principal investigators), J.D. Fisher, M.E. Josephson, E.N. Prystowsky, L. DiCarlo, D. Echt, G.S. Greer, D. Packer, and M. Talajic; **Events Committee:** J.D. Fisher (chair), P. Denes, J. DiMarco, D. Echt, M. Lehmann, D. Packer, and D. Roy; **Data Coordinating Center:** Duke University Clinical Research Institute, Durham, N.C. — K.L. Lee (director), G. Hafley, K. Pieper, and G. Marcucci (statisticians), V. Christian, J. Wehbie, and T. Gentry (project managers), S. Cress (data manager), and P. Smith, J. Wood, M. Palcisko, and G. Esposito (nurse coordinators); **Consultant:** J. Mason; **National Heart, Lung, and Blood Institute:** M. Domanski (project officer) and M. Proschan (statistician); **Data and Safety Monitoring Board:** B. Chaitman (chair), K. Bailey, B. Brody, J. Cohn, H.L. Greene, A. Hallstrom, and R. Lazzara. **Investigators** (the study sites and investigators participating in the Multicenter Unsustained Tachycardia Trial are listed according to the numbers of patients enrolled; for each site, the first person listed was the principal investigator): *Michigan Heart, Ann Arbor:* L. DiCarlo, S. Winston, D. Myers; *Northside Cardiology, Indianapolis:* E.N. Prystowsky, J. Evans, L. Jacobs, L. Janeira, M. Markel, R.I. Fogel; *Arkansas Cardiology Clinic, Little Rock:* G.S. Greer, J. Swaim; *Temple University Hospital School of Medicine, Philadelphia:* J.M. Miller, A.E. Buxton, H.H. Hsia, S.A. Rothman, G. Harper, L. Siddoway, S. Zukerman, D. Whitley, C. Slater, M. Gastineau, J. Edinger, D. Ackerman, N. Bowe; *University of Maryland, Baltimore:* M.R. Gold, S. Shorofsky, R. Peters, D. Froman, H. Scott; *Mayo Foundation, Rochester, Minn.:* D. Packer, S.C. Hammil, A. Jahangir, T. Munger, M.J. Osborn, R.F. Rea, W.K. Shen, M.S. Stanton, C. Stevens; *Montefiore Medical Center, Bronx, N.Y.:* J.D. Fisher, K. Ferrick, S. Kim, J. Roth, L. Chinitz, T. Glotzer, A. Ferrick, J. Durkin; *Midwest Heart Research Foundation, Lombard, Ill.:* M.F. O'Toole, M.O. Nora, E. Enger, J. Gurgone, K. Treckler; *Columbia University, New York:* J. Coromilas, J. Zimmerman, J. Reiffel, F. Livelli, K. Hickey; *Montreal Heart Institute, Montreal:* M. Talajic, D. Roy, M. Dubuc, D. Beaudoin, J. Marquis; *University of Pennsylvania, Philadelphia:* A.E. Buxton, M.E. Josephson, M. Hanna, N. Britton, K. Gephardt, L. Goffredo; *Electrophysiology Consultants, Detroit:* M.H. Lehmann, R.T. Steinman, J.J. Baga, L.A. Pires, C.D. Schuger, D. Frankovich, J. Fresard; *University of Ottawa Heart Institute, Ottawa, Ont., Canada:* A. Tang, M. Green, C. Carey; *University of Calgary, Calgary, Alta., Canada:* D.G. Wyse, H.J. Duff, A.M. Gillis, T.M. Kieser, L.B. Mitchell, J.M. Rothschild, R.S. Sheldon, J. Kellen, D. Ritchie, B. Baptie; *Yale University, New Haven, Conn.:* W.P. Batsford, C. McPherson, A. VanZetta, G. Elwood; *University of Nebraska Medical Center, Omaha:* J. Windle, W. Barrington, A. Easley, L. Smith; *Cardiology Associates, Johnson City, N.Y.:* N. Stamato, D. Whiting; *Cardiology Foundation of Lanekau Hospital, Wynnwood, Pa.:* P. Kowey, R.A. Marinchak, S.J. Rials, A.M.R. Chikowski, H. Criner; *State University of New York Health Science Center, Brooklyn:* N. El-Sherif, G. Turitto, L. Knudson; *New York Medical College, White Plains:* D.A. Rubin, C. Sorbera, A. McAllister; *University of Connecticut Health Center, Farmington:* E. Berns, M.B. Barry, L. Kearney, P. Stefanow, P. Malone; *Washington University, St. Louis:* M.E. Cain, J. Osborn; *University of Texas Southwestern Medical Center, Dallas:* R.L. Page, J.A. Joglar, G. Erwin, L. Nelson; *Mt. Sinai Medical Center, New York:* J.A. Gomes, S.L. Winters, E. Pe; *Sentara Norfolk General Hospital, Norfolk, Va.:* R.C. Bernstein, J.M. Herre, J. Onufer, L. McGowan, L. Klevan, C. Townsend; *Audubon Regional Medical Center, Louisville, Ky.:* J.M. Kammerling, V. Payne, J. Hanrahan; *Veterans Affairs Medical Center, Washington, D.C.:* S. Singh, R. Fletcher, R. Woosley, D. Byrns, B. Bennett; *Southern New Hampshire Cardiology Center, Manchester:* B. Hook, L. Brown; *University of Massachusetts, Worcester:* R.S. Mittleman, S.K.S. Huang, A.B. Wagshal, K.A. Rofino, K. Rofino; *St. Luke's Hospital, Kansas City, Mo.:* R. Lemery, D. Steinhaus, D. Cardinale; *Thoracic and Cardiovascular Institute, Lansing, Mich.:* J.H. Ip, D. Grimes, T. Magnum, B. McAndrews; *Vanderbilt University, Nashville:* D. Echt, D. Roden, N. Connors; *Tulane University School of Medicine, New Orleans:* M. Prior, J. Talano, N. Wicker; *Duke University Medical Center, Durham, N.C.:* R.A. Greenfield, H. Daniels, C. Grill; *Sutter Institute for Medical Research, Sacramento, Calif.:* G. O'Neill, A. Sharma, A. Skadsen; *Hôpital du Sacré-Coeur de Montréal, Montréal:* T. Kuss, R. Nadeau, G. Gaudette, J. Fouquette; *Lancaster Heart Foundation,*

Lancaster, Pa.: S. Worley, G. Rubright, J. Tuzi, K. Knepper; *University of Alabama at Birmingham, Birmingham*: S. Dailey, R. Bubien, C. Tidwell; *Cooper Hospital-University Medical Center, Camden, N.J.*: A.M. Russo, H. Waxman, C. Stubin, T. Meehan; *Sinai Hospital of Baltimore, Baltimore*: J. Reilly, D.J. Schamp, V. O'Mara; *Maine Medical Center, Portland*: J. Cutler, J. Love, C. Berg; *Medical Center Hospital of Vermont, Burlington*: M.A. Capeless, M. Rowen; *Pepin Heart and Vascular Institute, Tampa, Fla.*: C. Machado, S. Mester, C. Sullivan; *West Virginia University, Morgantown*: S.B. Schmidt; *Cardiac Disease Specialists, Atlanta*: T. Deering, S. Holt; *Hoag Memorial Hospital-Presbyterian Medical Center, Newport Beach, Calif.*: B. Kennelly, G. Mirabal, K. Porter; *Rockford Electrophysiology Consultants, Rockford, Ill.*: M. Hiser, T. Pham, E. Silva, P. Dittmar; *University of Louisville School of Medicine, Louisville, Ky.*: I. Singer, S. Blair, A. Cicic; *Iowa Heart Center, Des Moines*: W.B. Johnson, M. Core-Bier; *Beth Israel Deaconess Medical Center, Boston*: M.E. Josephson, R. Bayer, V. Schreckengost; *Staten Island University Hospital, Staten Island, N.Y.*: S. Bekheit-Saad, M.L. Bresznayak, A.V. Porter, E. Walsh; *Albany Medical College, Albany, N.Y.*: A. Portnow, J. Nattama, D. O'Dea, C. Ocampo, I. Megas-Nowak, T. Coulson; *Virginia Commonwealth University, Richmond*: M. Wood, K. Ellenbogen, B. Stambler, R. Sperry, M. Belz, V. Gillock, C. Dietrich, N. Michaels, D. Sargent; *Cardiology of Tulsa, Tulsa, Okla.*: J. Swartz, D.W. Frazier, W.O. Adkisson, R.D. Ensley, S. Dewald, L. Klahr; *Clearwater Cardiovascular Consultants, Largo, Fla.*: J. Gallastegui, K. Livingston; *Medical Center of Delaware, Newark*: H. Weiner, R. Vitullo, A. DiSabitino, S. Feels; *Rhode Island Hospital, Providence*: R. Lemery, E. Berger, C.A. Chmielewski, E. Connolly; *Presbyterian Hospital of Dallas, Dallas*: J. Hurwitz, B. Wimberly, D.D. Capper; *North Shore University Hospital, Manhasset, N.Y.*: R. Jadonath, T. Cohen, B. Goldner, D. Kalenderian, L. Chepurko; *Riverside Regional Medical Center, Newport News, Va.*: A. Murphy, S. Gessner, M. Barton, L. Heezen; *St. Francis Medical Center, Pittsburgh*: A. Ticzon, C. DiGiocomo, L. Predis; *University of New Mexico Health Science Center, Albuquerque*: G.M. Greenberg, R.M. Cataldo, T. Hudson, L. Beeman; *Veterans Affairs Medical Center, Ann Arbor, Mich.*: W. Kou, D. Randall; *Illinois Masonic Medical Center, Chicago*: R. Kehoe, S. Crandall, L. Farwell; *Heart Center, Sarasota, Fla.*: W. Hepp, Healy, H. Taylor; *Wichita Institute for Clinical Research, Wichita, Kans.*: G. Turitto, J.E. Val-Mejias, D. Klonis, P. Patterson; *University of Virginia Medical School, Charlottesville*: J. DiMarco, S. Thompson; *New York Hospital-Cornell Medical Center, New York*: B. Lerman, M. Sarmiento; *Harper Hospital, Detroit*: M.B. Meissner; *St. Paul-Ramsey Medical Center, St. Paul, Minn.*: P. Denes, L. Swenson, C. Vittum; *University of Florida, Gainesville*: A.B. Curtis, M. Mardis, M. LaTour; *St. Vincent Medical Center, Toledo, Ohio*: S. Brownstein, V. Duthinh, J. Morris, R. Oberhaus; *Cardiology Care Specialists, Allentown, Pa.*: L. Constantin, C. Kern, C. Fedak; *Medical College of Pennsylvania and Hahnemann University, Philadelphia*: D.J. Callans, F.E. Marchlinski, C.D. Gottlieb, C. Vrabel; *University of Pittsburgh, Pittsburgh*: K. Anderson, S. Fahrigh, B. Miklos; *Rush-Presbyterian-St. Luke's Medical Center, Chicago*: R. Mitra, P. Santucci, L.M. Ramirez-Morgen, P. Rapnikas; *Central Baptist Hospital, Lexington, Ky.*: M. Rukavina, K. Tincher; *Heart Clinics Northwest, Spokane, Wash.*: T. Lessmeir, J. Priggee, D. Westover; *University of Colorado Health Sciences Center, Denver*: P. Kelly, T. Heyborne; *Heart Care Midwest, Peoria, Ill.*: R. Bauernfeind, F.L. Gold, T. Wall; *Robert Wood Johnson Medical School, New Brunswick, N.J.*: M. Premlinger, N. Cosgrove; *Carle Clinic Association, Urbana, Ill.*: A. Kocherill, J. Shane, S. Lofrano; and *Mid-Florida Cardiology Specialists, Orlando*: M. Hazday, L. Jopperi.

REFERENCES

- de Vreede JJM, Gorgels APM, Verstraaten GMP, Vermeer F, Dassen WRM, Wellens HJJ. Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. *J Am Coll Cardiol* 1991; 18:698-706.
- McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. *N Engl J Med* 1996;334:884-90.
- Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s — their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. *J Am Coll Cardiol* 1996;27:1119-27.
- Tavazzi L, Volpi A. Remarks about postinfarction prognosis in light of the experience with the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI) trials. *Circulation* 1997;95:1341-5.
- de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouet WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. *J Am Coll Cardiol* 1997;30:1500-5.
- Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. *Am Heart J* 1989;117:151-9.
- Roy D, Marchand E, Theroux P, Waters DD, Pelletier GB, Bourassa MG. Programmed ventricular stimulation in survivors of an acute myocardial infarction. *Circulation* 1985;72:487-94.
- Bhandari AK, Rose JS, Kotlewski A, Rahimtoola SH, Wu D. Frequency and significance of induced sustained ventricular tachycardia or fibrillation two weeks after acute myocardial infarction. *Am J Cardiol* 1985;56:737-42.
- Iesaka Y, Nogami A, Aonuma K, et al. Prognostic significance of sustained monomorphic ventricular tachycardia induced by programmed ventricular stimulation using up to triple extrastimuli in survivors of acute myocardial infarction. *Am J Cardiol* 1990;65:1057-63.
- Bourke JP, Richards DAB, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. *J Am Coll Cardiol* 1991;18:780-8.
- Richards DAB, Byth K, Ross DL, Uther JB. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction? *Circulation* 1991;83:756-63.
- Gomes JAC, Hariman RI, Kang PS, El-Sherif N, Chowdhry I, Lyons J. Programmed electrical stimulation in patients with high-grade ventricular ectopy: electrophysiologic findings and prognosis for survival. *Circulation* 1984;70:43-51.
- Buxton AE, Marchlinski FE, Flores BT, Miller JM, Doherty JU, Josephson ME. Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiologic study. *Circulation* 1987;75:1178-85.
- Klein RC, Machell C. Use of electrophysiologic testing in patients with nonsustained ventricular tachycardia: prognostic and therapeutic implications. *J Am Coll Cardiol* 1989;14:155-61.
- Wilber DJ, Olshansky B, Moran JE, Scanlon PJ. Electrophysiological testing and nonsustained ventricular tachycardia: use and limitations in patients with coronary artery disease and impaired ventricular function. *Circulation* 1990;82:350-8.
- Kadish A, Schmaltz S, Calkins H, Morady F. Management of nonsustained ventricular tachycardia guided by electrophysiological testing. *Pacing Clin Electrophysiol* 1993;16:1037-50.
- Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. *N Engl J Med* 1999;341:1882-90.
- Buxton AE, Fisher JD, Josephson ME, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). *Prog Cardiovasc Dis* 1993;36:215-26.
- Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. *Circulation* 1982;65:457-64.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457-81.
- Kalbfleisch JD, Prentice RL. *The statistical analysis of failure time data*. New York: John Wiley, 1980.
- Cox DR. Regression models and life-tables. *J R Stat Soc [B]* 1972;34:187-220.
- Turitto G, Ahuja RK, Caref EB, el-Sherif N. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. *J Am Coll Cardiol* 1994;24:1523-8.
- Meinertz T, Treese N, Kasper W, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. *Am J Cardiol* 1985;56:337-41.
- Stamato NJ, O'Connell JB, Murdock DK, Moran JE, Loeb HS, Scanlon PJ. The response of patients with complex ventricular arrhythmias secondary to dilated cardiomyopathy to programmed electrical stimulation. *Am Heart J* 1986;112:505-8.
- Das SK, Morady F, DiCarlo L Jr, et al. Prognostic usefulness of programmed ventricular stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias. *Am J Cardiol* 1986;58:998-1000.
- Poll DS, Marchlinski FE, Buxton AE, Josephson ME. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. *Am J Cardiol* 1986;58:992-7.
- Buxton AE, Hafley GE, Lehmann MH, et al. Prediction of sustained ventricular tachycardia induced by programmed stimulation in patients with coronary artery disease: utility of clinical variables. *Circulation* 1999; 99:1843-50.
- Roy D, Marchand E, Theroux P, et al. Long-term reproducibility and significance of provokable ventricular arrhythmias after myocardial infarction. *J Am Coll Cardiol* 1986;8:32-9.
- Kuck KH, Costard A, Schluter M, Kunze KP. Significance of timing programmed electrical stimulation after acute myocardial infarction. *J Am Coll Cardiol* 1986;8:1279-88.

- 31.** Bhandari AK, Au PK, Rose JS, Kotlewski A, Blue S, Rahimtoola SH. Decline in inducibility of sustained ventricular tachycardia from two to twenty weeks after acute myocardial infarction. *Am J Cardiol* 1987;59:284-90.
- 32.** Bhandari AK, Hong R, Kulick D, et al. Day to day reproducibility of electrically inducible ventricular arrhythmias in survivors of acute myocardial infarction. *J Am Coll Cardiol* 1990;15:1075-81.
- 33.** Nogami A, Aonuma K, Takahashi A, et al. Usefulness of early versus late programmed ventricular stimulation in acute myocardial infarction. *Am J Cardiol* 1991;68:13-20.